ArticleAmerican journal of cancer research2017

Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer.

Sha Shi et al.PubMed ↗Full text ↗

No numbers read from the abstract.